Cabaletta: Headwinds And Funding Issues, But Also Clear Clinical Direction (NASDAQ:CABA)

Cabaletta plans a BLA submission for myositis in 2027, supported by the FDA's RMAT designation and a focused clinical trial strategy. Learn more on CABA stock here.